[go: up one dir, main page]

WO1999026606A3 - SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS - Google Patents

SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS Download PDF

Info

Publication number
WO1999026606A3
WO1999026606A3 PCT/EP1998/007198 EP9807198W WO9926606A3 WO 1999026606 A3 WO1999026606 A3 WO 1999026606A3 EP 9807198 W EP9807198 W EP 9807198W WO 9926606 A3 WO9926606 A3 WO 9926606A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained release
release formulations
glucosidase
inhibitors
emiglitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/007198
Other languages
French (fr)
Other versions
WO1999026606A2 (en
Inventor
David Goldman
John Amatruda
Carola Poertner
Erich Brendel
Patrick Bosche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to JP2000521808A priority Critical patent/JP2001523704A/en
Priority to AU12343/99A priority patent/AU1234399A/en
Publication of WO1999026606A2 publication Critical patent/WO1999026606A2/en
Publication of WO1999026606A3 publication Critical patent/WO1999026606A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical sustained release formulations of α-glucosidase inhibitors as for example acarbose, miglitol, emiglitate or voglibose leading to a reduction of side effects.
PCT/EP1998/007198 1997-11-25 1998-11-11 SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS Ceased WO1999026606A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000521808A JP2001523704A (en) 1997-11-25 1998-11-11 Sustained release formulation comprising an α-glucosidase inhibitor
AU12343/99A AU1234399A (en) 1997-11-25 1998-11-11 Sustained release formulations comprising alpha-glucosidase-i nhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6669897P 1997-11-25 1997-11-25
US60/066,698 1997-11-25

Publications (2)

Publication Number Publication Date
WO1999026606A2 WO1999026606A2 (en) 1999-06-03
WO1999026606A3 true WO1999026606A3 (en) 1999-08-12

Family

ID=22071124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/007198 Ceased WO1999026606A2 (en) 1997-11-25 1998-11-11 SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS

Country Status (5)

Country Link
JP (1) JP2001523704A (en)
AR (1) AR017664A1 (en)
AU (1) AU1234399A (en)
WO (1) WO1999026606A2 (en)
ZA (1) ZA9810710B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143225A (en) * 2000-05-24 2008-03-20 Pfizer Preparation of medicaments containing alpha-amylase inhibitors for the treatment of rumen acidosis
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004014932A1 (en) 2002-08-08 2004-02-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP4902348B2 (en) 2004-03-04 2012-03-21 キッセイ薬品工業株式会社 Nitrogen-containing fused ring derivative, pharmaceutical composition containing it, and pharmaceutical use thereof
CN102631332A (en) * 2012-04-28 2012-08-15 邹立兴 Voglibose tablet and preparation method thereof
CN104013590A (en) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 Acarbose-containing medicinal composition and preparation method thereof
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
EP3233066B1 (en) * 2014-12-17 2021-11-10 Empros Pharma AB A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
CN110898025A (en) * 2019-12-12 2020-03-24 湖北欣泽霏药业有限公司 Acarbose sustained-release preparation and preparation method thereof
CN111265489A (en) * 2020-03-10 2020-06-12 乐普制药科技有限公司 Divisible acarbose pellet sustained-release tablet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073428A2 (en) * 1981-09-01 1983-03-09 Bayer Ag Medicinal preparations for glycoside-hydrolase inhibitors
EP0194794A2 (en) * 1985-03-08 1986-09-17 Takeda Chemical Industries, Ltd. Saccharide digestion inhibiting composition
EP0364696A2 (en) * 1988-08-22 1990-04-25 Takeda Chemical Industries, Ltd. Alpha-glucosidase inhibitor as a calcium absorption promotor
EP0610854A1 (en) * 1993-02-10 1994-08-17 Takeda Chemical Industries, Ltd. Tablets with improved abrasion resistance and method to produce them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073428A2 (en) * 1981-09-01 1983-03-09 Bayer Ag Medicinal preparations for glycoside-hydrolase inhibitors
EP0194794A2 (en) * 1985-03-08 1986-09-17 Takeda Chemical Industries, Ltd. Saccharide digestion inhibiting composition
EP0364696A2 (en) * 1988-08-22 1990-04-25 Takeda Chemical Industries, Ltd. Alpha-glucosidase inhibitor as a calcium absorption promotor
EP0610854A1 (en) * 1993-02-10 1994-08-17 Takeda Chemical Industries, Ltd. Tablets with improved abrasion resistance and method to produce them

Also Published As

Publication number Publication date
AU1234399A (en) 1999-06-15
ZA9810710B (en) 1999-06-14
JP2001523704A (en) 2001-11-27
WO1999026606A2 (en) 1999-06-03
AR017664A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
CA2251453A1 (en) 5-arylalkyl-substituted pyrazolo(4,3-d)pyrimidine-7-ones
WO2001032646A3 (en) Sulfonamide derivatives
PL319605A1 (en) Novel benzoxazoles
AU1690399A (en) Neovascularization inhibitor containing dienogest as the active ingredient
AU3192495A (en) N,n-disubstituted amic acid derivative
AU9254698A (en) Thickening agents for acidic aqueous compositions
NO20002217L (en) Cyclopentane-heptanoic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU6310000A (en) Aerosol formulations
NO20003150D0 (en) Procedure for the preparation of tablets dissolved by chewing
DK0747050T4 (en) Pharmaceutical compositions containing irbesartan
ZA200201862B (en) Electrostatic aerosol compositions.
EP0819000A4 (en) Nodulisporic acid derivatives
CA2367724A1 (en) Packaging system for cosmetic formulations
HUP0004071A3 (en) Pharmaceutical compositions comprising prostaglandin derivatives
WO1999026606A3 (en) SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
AU2496400A (en) Topical compositions comprising functional nucleophiles protected by phosphorus-containing moieties
CA2362698A1 (en) Resorcinol derivatives
AU6386801A (en) System for the release of active ingredients
AU1025799A (en) Thickening agents for acidic aqueous compositions
EP1019047A4 (en) Antithrombotic agents
FR2799381B1 (en) SPRAY HEAD, ESPECIALLY FOR FIRE FIGHTING INSTALLATION
WO1998046632A3 (en) Inhibitors for urokinase receptor
CA2366623A1 (en) Resorcinol composition
CA2214072A1 (en) Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998955566

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09554153

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998955566

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA